Reviewing the Leadership Transition in Semmelweis University’s Department of Neurology
Effective July 1, the Department of Neurology at Semmelweis University in Hungary welcomed a new director: Dr. Tibor Kovács. Taking the reins following the retirement of Dr. Dániel Bereczki, Dr. Kovács brings 32 years of dedicated experience to the role, including two decades serving as the department’s deputy director. For medical professionals and students observing the landscape of neurological care in Central Europe, this leadership change signals a continued, aggressive push toward integrating advanced biological therapies into standard clinical practice.
Dr. Kovács’s appointment is not a sudden shift in direction but rather a consolidation of ongoing efforts. He describes the transition as moving from the “second division” to an “era of independent competition.” Because he has spent the last 20 years deeply involved in the clinic’s operational management, his ascent to the directorship ensures stability. The department’s staff, the educational frameworks, and the patient care protocols remain familiar to him, allowing for a seamless continuation of high-level neurological services and academic instruction.
Analyze the Clinical and Academic Background of Dr. Tibor Kovács
Understand the foundation upon which Dr. Kovács leads. A graduate of the University of Szeged, he earned his medical degree in 1992, already boasting three years of experience teaching neuroanatomy in both Hungarian and English. His clinical foundation was built at Semmelweis University, where he became a resident in November 1994. His career trajectory is distinguished by multiple board certifications—he passed his neurology boards in 1997, neuropathology in 2005, and clinical pharmacology in 2010.
His early career was heavily influenced by Professor Mátyás Papp, an internationally recognized neurologist and neuropathologist. Under Papp’s mentorship, Dr. Kovács was exposed to high-level clinical neuroscience, including work related to the Papp-Lantos bodies—inclusions critical for the histological diagnosis of multiple system atrophy. This represents one of the most significant Hungarian contributions to clinical neuroscience. This early exposure led to research fellowships at the Institute of Psychiatry at King’s College London, where he trained in neuropathology and pathology under Dr. Peter Lantos.
Dr. Kovács’s academic credentials are equally robust, having earned his PhD from Semmelweis University in 2001 with research focusing on the neuropathology of the olfactory system in Alzheimer’s disease patients, followed by his habilitation in 2005. This deep background in both the clinical and morphological aspects of neurodegenerative diseases directly informs the department’s current strategic priorities.
Schedule a free consultation to learn more about our neurological programs.
Assess the Operational Scale and Educational Demands
Operating the Department of Neurology at Semmelweis University requires managing a massive logistical undertaking. The department achieves its clinical and academic goals with a relatively compact team of just 40 doctors. Despite this lean staffing, the department educates approximately 1,500 students annually. These students come from the Faculty of Medicine (ÁOK), the Faculty of Dentistry (FOK), and the Faculty of Health Sciences (ETK). Beyond undergraduate education, the department is heavily involved in specialist training, PhD programs, and other professional continuing education courses.
Patient care volumes further illustrate the department’s intensive workload. In inpatient care, the department consistently provides services up to the limits set by the service volume cap and prescription cap. However, the outpatient sector has experienced exponential growth. Over the past 10 to 15 years, outpatient cases have doubled, resulting in an impressive and demanding 45,000 to 48,000 outpatient visits per year. Managing this volume requires precise scheduling, efficient triage, and a robust infrastructure capable of handling a high turnover of complex neurological cases.
Navigating Inpatient and Outpatient Dynamics
The dichotomy between inpatient and outpatient care presents unique challenges. Inpatient care at the department is primarily driven by stroke treatment, which requires rapid, resource-intensive interventions, alongside the management of severe degenerative and neurological diseases. Conversely, the outpatient clinic deals with long-term management, follow-ups, and increasingly, the administration of complex biological therapies. Balancing the acute needs of inpatient stroke care with the chronic, resource-heavy demands of outpatient neuroimmunology and dementia care requires constant operational recalibration.
Implementing Biological Therapies for Alzheimer’s Disease
One of the most significant developments currently underway at Semmelweis University is the integration of biological therapies for Alzheimer’s disease. Approved by the European Union in 2025, these treatments represent a paradigm shift in how neurodegenerative diseases are managed. Dr. Kovács notes that the department is actively working to introduce these therapies into outpatient care, pending the finalization of funding, prescribing guidelines, and accessibility protocols.
Implementing these biological therapies is not a simple matter of writing a prescription. The procedure is highly complex, requiring extensive interdisciplinary collaboration. It demands significant time and resources, starting with rigorous patient screening. Theoretically, only about 15 to 20 percent of Alzheimer’s patients are eligible for this specific class of drugs, making the screening process itself a highly specialized diagnostic hurdle.
Once a patient is identified as a candidate, the resource intensity only increases. The procedure requires numerous MRI scans to monitor brain volume and amyloid plaque levels, comprehensive laboratory testing, genetic testing to identify risk factors like the APOE genotype, and detailed neuropsychological testing to establish baseline cognitive function and track efficacy. Semmelweis University holds a distinct advantage in this arena: it is the only clinical trial center in Hungary whose researchers possess direct experience with this specific disease and class of drugs. Their prior involvement in drug trials has prepared the team for the rigorous diagnostic and follow-up requirements these biological therapies demand.
Explore our related articles for further reading on medical advancements.
Expanding Biological Treatments for Neuroimmunological Diseases
Alzheimer’s disease is not the only area where biological therapies are reshaping clinical practice. Neuroimmunological diseases, particularly multiple sclerosis (MS), are also seeing a rapid expansion in biologic treatment options. Dr. Kovács highlights the exponentially growing number of patients requiring these advanced therapies, coupled with the practical limitations on the use of intravenous immunoglobulin (IVIG) in this patient group.
Many neuroimmunological conditions require long-term treatment in outpatient settings due to the chronic, recurring nature of the diseases. The therapeutic use of biologic agents for multiple sclerosis necessitates dedicated outpatient infusion capacity. Patients must be scheduled for regular, supervised infusions, requiring specialized nursing staff, infusion chairs, monitoring equipment, and specific pharmaceutical storage facilities. This requirement for dedicated infusion capacity mirrors the logistical needs of the dementia and Alzheimer’s biological therapies. As demand for both groups of conditions continues to rise, the department must actively expand its outpatient infrastructure to accommodate the growing patient load without compromising safety or efficacy.
Additionally, the department serves as a national center for biological therapy targeting headaches, further diversifying its outpatient infusion responsibilities and cementing its role as a central hub for advanced neurological treatments in Hungary.
Addressing the Nursing Shortage in Neurological Care
Despite the exciting advancements in pharmacological treatments, Dr. Kovács identifies the shrinking nursing staff as the most serious operational challenge facing the department. Neurology is an inherently nursing-intensive specialty. Many neurological patients suffer from limited mobility, severe sensory deficits, or cognitive impairments that require assistance with basic self-care, positioning, and continuous monitoring.
The department currently works with a well-established, highly skilled nursing team. However, recruitment is lagging. With retirements, illnesses, and a lack of new hires, the workforce is shrinking even without factoring in professionals actively leaving the field. This shortage puts immense pressure on the existing staff and limits the department’s ability to expand its bed capacity or take on more complex cases that require intensive nursing care. While Dr. Kovács notes that there is no shortage of medical specialists applying to the field, the bottleneck clearly lies in the nursing infrastructure. Solving this will likely require systemic changes in how nursing roles are compensated and supported within the healthcare system.
Submit your application today to join the next generation of medical professionals.
Balancing Clinical Practice, Management, and Neuropathological Research
Assuming the role of director has fundamentally shifted the balance of Dr. Kovács’s daily work. For decades, he functioned primarily as a clinician managing a very large personal caseload. Now, management and administrative duties consume a significant portion of his schedule. He has had to hand over many of his direct patient care responsibilities to his colleagues, reducing his involvement with new admissions. Among his administrative challenges is the continued need to refine his approach to delegating responsibilities and outsourcing non-clinical tasks.
Despite these administrative burdens, Dr. Kovács remains committed to his clinical and research roots. He intends to maintain a focus on morphology and the neuropathological aspects of anatomy, dedicating at least one day a week to this discipline. In his capacity as the head of the Reference Center for Neuropathology and Prion Diseases, he works alongside Dr. Krisztina Danics. Together, they examine microscopic brain tissue samples from individuals who have died of suspected prion diseases—such as Creutzfeldt-Jakob disease—to establish definitive diagnoses. Dr. Kovács is one of the very few specialists in Hungary who holds a board certification in neuropathology, making his continued involvement in this reference center critical for the country’s public health infrastructure.
Conclusion
The Department of Neurology at Semmelweis University is navigating a period of intense transition and growth. Under the leadership of Dr. Tibor Kovács, the department is leveraging its decades of clinical trial experience to integrate complex biological therapies for Alzheimer’s disease, multiple sclerosis, and severe headaches into standard outpatient care. While these medical advancements offer new hope for patients with neurodegenerative and neuroimmunological conditions, they also place heavy demands on the department’s physical and human infrastructure. As Semmelweis University continues to educate the next generation of medical professionals and serve as a national referral center, addressing the parallel challenges of nursing shortages and outpatient infusion capacity will be just as important as the biological innovations themselves.
Have questions? Write to us to discuss these neurological treatments.
Share your experiences in the comments below regarding biological therapies in neurology.
